

BARD1 RECEIVES \$464,101 R&D TAX REFUND

- **R&D tax refund of \$464,101 received for the 2019 financial year**

Perth, Australia, 20 April 2020: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**), a medical technology company developing non-invasive cancer diagnostics, today advised the Company has received its Research and Development (R&D) Tax refund of \$464,101 for the 2019 financial year.

BARD1's 2019 R&D Application included eligible R&D expenditure of \$1,066,899 from Australia and overseas, resulting in a 43.5% R&D tax refund of \$464,101 from the Australian Taxation Office (ATO). The funds will be reinvested into progressing the development and commercialisation of the BARD1 diagnostics pipeline.

The R&D Tax Incentive Scheme supports companies to invest in R&D activities in Australia by providing cash rebates of 43.5% for eligible R&D expenditure. BARD1 received a "*R&D Tax Incentive – Advance and Overseas Finding Certificate*" from AusIndustry on 18 February 2019 approving that its overseas R&D activities, in addition to its Australian activities, are eligible for the R&D Tax Incentive in the financial years 2017/18, 2018/19 and 2019/20.

- ENDS -

COMPANY CONTACTS:

Dr Leearne Hinch

CEO

E leearne@bard1.com

M +61 400 414 416

Peter Gunzburg

Chairman

E peter@bard1.com

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of ovarian, breast and lung cancers. BARD1's mission is to detect cancer earlier and save lives. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.